- Home
- ACRV vs PYPD Comparison
ACRV vs PYPD Comparison
Compare ACRV & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- PYPD
- Stock Information
- Founded
- ACRV 2018
- PYPD 2008
- Country
- ACRV United States
- PYPD Israel
- Employees
- ACRV N/A
- PYPD N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- PYPD Medical/Dental Instruments
- Sector
- ACRV Health Care
- PYPD Health Care
- Exchange
- ACRV Nasdaq
- PYPD Nasdaq
- Market Cap
- ACRV 40.4M
- PYPD 36.0M
- IPO Year
- ACRV 2022
- PYPD 2020
- Fundamental
- Price
- ACRV $1.26
- PYPD $3.41
- Analyst Decision
- ACRV Buy
- PYPD Strong Buy
- Analyst Count
- ACRV 7
- PYPD 5
- Target Price
- ACRV $17.60
- PYPD $11.40
- AVG Volume (30 Days)
- ACRV 287.7K
- PYPD 108.0K
- Earning Date
- ACRV 08-12-2025
- PYPD 08-13-2025
- Dividend Yield
- ACRV N/A
- PYPD N/A
- EPS Growth
- ACRV N/A
- PYPD N/A
- EPS
- ACRV N/A
- PYPD N/A
- Revenue
- ACRV N/A
- PYPD N/A
- Revenue This Year
- ACRV N/A
- PYPD N/A
- Revenue Next Year
- ACRV $1,037.93
- PYPD N/A
- P/E Ratio
- ACRV N/A
- PYPD N/A
- Revenue Growth
- ACRV N/A
- PYPD N/A
- 52 Week Low
- ACRV $1.05
- PYPD $2.30
- 52 Week High
- ACRV $10.16
- PYPD $3.93
- Technical
- Relative Strength Index (RSI)
- ACRV 43.05
- PYPD 44.72
- Support Level
- ACRV $1.34
- PYPD $3.63
- Resistance Level
- ACRV $1.48
- PYPD $3.85
- Average True Range (ATR)
- ACRV 0.10
- PYPD 0.17
- MACD
- ACRV -0.01
- PYPD -0.05
- Stochastic Oscillator
- ACRV 17.24
- PYPD 18.03
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.